Michael  Halpin net worth and biography

Michael Halpin Biography and Net Worth

COO of Vericel
Mike joined Vericel in April of 2017 with over 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies. Prior to joining Vericel, Mike was with Sanofi and Genzyme Corporation; most recently as vice president, North American region regulatory head with responsibility for Sanofi Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Mike has also served as vice president, regulatory affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel®, Epicel®, and MACI®. Prior to Genzyme, Mike held a number of regulatory, quality, and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard, and Abiomed. Mike received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.

What is Michael Halpin's net worth?

The estimated net worth of Michael Halpin is at least $41,509.26 as of March 11th, 2024. Mr. Halpin owns 949 shares of Vericel stock worth more than $41,509 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Halpin may own. Additionally, Mr. Halpin receives an annual salary of $796,910.00 as COO at Vericel. Learn More about Michael Halpin's net worth.

How old is Michael Halpin?

Mr. Halpin is currently 63 years old. There are 4 older executives and no younger executives at Vericel. Learn More on Michael Halpin's age.

What is Michael Halpin's salary?

As the COO of Vericel Co., Mr. Halpin earns $796,910.00 per year. The highest earning executive at Vericel is Mr. Dominick C. Colangelo Esq., CEO, President & Director, who commands a salary of $1,540,000.00 per year. Learn More on Michael Halpin's salary.

How do I contact Michael Halpin?

The corporate mailing address for Mr. Halpin and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at [email protected]. Learn More on Michael Halpin's contact information.

Has Michael Halpin been buying or selling shares of Vericel?

Michael Halpin has not been actively trading shares of Vericel during the last ninety days. Most recently, Michael Halpin sold 7,874 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $44.71, for a transaction totalling $352,046.54. Following the completion of the sale, the chief operating officer now directly owns 949 shares of the company's stock, valued at $42,429.79. Learn More on Michael Halpin's trading history.

Who are Vericel's active insiders?

Vericel's insider roster includes Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), and Paul Wotton (Director). Learn More on Vericel's active insiders.

Are insiders buying or selling shares of Vericel?

During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 87,693 shares worth more than $3,772,233.03. The most recent insider tranaction occured on April, 18th when CEO Dominick Colangelo sold 17,500 shares worth more than $780,325.00. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.

Information on this page was last updated on 4/18/2024.

Michael Halpin Insider Trading History at Vericel

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Sell7,874$44.71$352,046.54949View SEC Filing Icon  
10/26/2021Sell10,000$50.57$505,700.00View SEC Filing Icon  
7/12/2021Sell20,000$53.54$1,070,800.00View SEC Filing Icon  
6/23/2020Sell14,751$15.01$221,412.51
11/11/2019Sell15,047$18.53$278,820.91View SEC Filing Icon  
See Full Table

Michael Halpin Buying and Selling Activity at Vericel

This chart shows Michael Halpin's buying and selling at Vericel by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vericel Company Overview

Vericel logo
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $43.74
Low: $42.38
High: $44.50

50 Day Range

MA: $47.58
Low: $43.74
High: $52.90

2 Week Range

Now: $43.74
Low: $29.24
High: $53.05

Volume

521,989 shs

Average Volume

554,959 shs

Market Capitalization

$2.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71